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Success of Antibody-drug conjugates (ADCs) relies on the maintained integrity of a chemical linker 
fusing a therapeutic payload to a monoclonal antibody. Recent reports have revealed the lead linker 
ValCitPABC has poor stability in rodent models compared to mammalian counterparts, resulting in many 
clinical investigations predicting poorer ADC efficacy due to premature payload release in these model 
systems. Optimization of this chemical linker to be resistant both in mouse and human models would 
streamline ADC progression into clinical trials. Herein we describe the synthesis and development of a 
FRET-based assay for evaluating linker stability in vitro. Evaluation of lysosomal release by catabolic 
proteases paired with serum stability testing identified a series of asparagine containing linkers which 
surpassed both the release kinetics and stability profiles of ValCitPABC. A synthetic scheme for MMAE 
attachment to these asparagine linkers was established. Ultimately, this work lays a foundation for future 
evaluation of these linker in vivo for the identification of next generation peptide linkers to surpass the 
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1.1 Antibody Drug Conjugate Composition  
Targeted-drug delivery has grown in prevalence over the past several decades as a means to bypass off 
target side effects from systemic administration of a biologically active compound.1 This philosophy has 
grown in importance within oncology, where classical cytotoxic agents have targeted rapidly dividing 
malignant cells, concurrently acting on erythrocytes, leukocytes, and keratinocytes leading to problematic 
side effects. Antibody-drug conjugates (ADC) offer an active targeting mechanism to eliminate a cell type 
of interest by fusing a potent payload to an antibody which recognizes a selectively expressed cell surface 
antigen.2 Comprised of a monoclonal antibody, chemical linker and therapeutic payload, ADC efficacy 
and pharmacokinetics are entangled with the interactions between these three components and the cell 
machinery they come in contact with.  
Careful payload delivery is achieved through the selection of a monoclonal antibody (mAb) with high 
affinity towards a selectively expressed cell surface antigen. The targeted receptor must maintain a 
mechanism of clathrin-mediated endocytosis to enable ADC entry into the cell for internal payload 
release.2 Most ADC applications see light in oncology, with typical cytotoxic payloads interacting with 
DNA (PBD, DUO) or microtubules (MMAE, MMAF, DM1).3–7 Ideally, a payload should be released 
from the conjugate in an unmodified state, but several payloads have been demonstrated to tolerate 
structural modifications at the linkage site.6,8 The linker chemistry conjoins the payload to a mAb and 
contains a controlled mechanism of release spanning disulfide, hydrazone, and peptide functionalities 
which exploit the intracellular environment (glutathione reduction of disulfides in cytoplasm, acid 
hydrolysis of hydrazones in lysosome, and proteolytic cleavage of peptide linkers).9,10 Fusion of the 
linker-payload to the antibody is accomplished through conjugation strategies including lysine amide 
coupling, cysteine coupling and enzymatic conjugation.10 Given the four native cysteine disulfide 
linkages in mAbs, cysteine conjugation is a simple and reliable method of attaching upwards of eight 




optimization of this linkage, as pharmacokinetic parameters of stability in circulation, rate of release and 
catabolic transformation encompass linker chemistries. Currently, five ADCs are approved for clinical use 
by the US Food and Drug Administration (FDA) with over 80 currently in clinical trials, demonstrating 
the exciting promise this modality brings to therapeutic applications.9  
1.2 The mcValCitPABC Lead Linker and Extracellular Stability Concerns 
Currently, two FDA approved ADCs, Adcetris and Polivy, utilize a cysteine conjugation technique and 
proteolytic release mechanism with a leading Valine-Citrulline-p-aminobenzyl carbamate (ValCitPABC) 
linker.11,12 Payload release from ValCitPABC utilizes cathepsin B, a cysteine protease, to hydrolyze the 
amide bond between citrulline and PABC, forcing 1,4-elimination mechanism to release the unmodified 
payload (fig. 1). Like all linkers, this cleavage mechanism is essential for successful payload release 





































Figure 1. Cathepsin B Mediated cleavage and subsequent 1,4-elimination of the payload  
Recent discoveries have revealed the ValCitPABC linker to be more unstable in circulation than 
previously believed. Surprisingly, an extracellular serine hydrolase Carboxyesterase 1C (Ces1C) was 
identified as capable of releasing payloads.13 While believed to hydrolyze the amide bond adjacent to 
PABC like lysosomal proteases, additional reports indicate the carbamate may susceptible to hydrolysis 
by Ces1C resulting in payload loss as well.14 These stability concerns are most prevalent in mouse and rat 
studies, with primate studies revealing less significant cleavage.15 This stability differential is problematic 
for evaluating potential ADC efficacy and safety, as non-primate models are used as a primary method of 






lead time for in vivo studies.14 While site-selective ADCs showed promise in enhancing stability, recent 
reports these selections also result in premature payload release.16 In addition to Ces1C, neutrophil 
elastase has been shown to hydrolyze the ValCitPABC linker resulting in neutropenia.17 
The most promising method to alleviate these concerns have involved modifications to the amino acid 
composition at the P3 position of P3-Val-Cit-PABC linkages, resulting in more robust linkers in mouse 
models.13,18  We have adopted a similar methodology, by interrogating both the P2 and P1 positions of the 
linker in hopes of identifying a series of linker chemistries with enhanced extracellular stability profiles 
while still utilizing a proteolytic lysosomal release mechanism.  
2 Methodology  
2.1 Linker Design 
Linkers were designed to mimic the structure of mcValCitPABC while retaining a synthesis to allow an 
easy interchange of amino acids to interrogate the P1 and P2 positions of proteases. The resulting Mal-
AEEA-Gly-P2-P1-COOH linker was designed as a model system matching the above criterion. An N-
terminal maleimide enabled future Michael addition including cysteine conjugations, the AEEA-Gly 
components mimicked the caproyl spacer seen in the traditional linker, and the P2 and P1 positions held 
varying amino acids chosen to span chemical space. A total of 75 peptides were prepared by WuXi 
AppTec providing 15-30mg of each designed peptide. Completing the mimic of mcValCitPABC, a p-
aminobenzyl amine moiety was attached to the C-terminus of Mal-AEEA-Gly-P2-P1-COOH linkers, and 
an amide linkage at the benzylic position connected a desired payload for screening purposes (Fig. 2A).  
2.2 FRET-Based Assay 
Screening of lysosomal lability and extracellular stability of each proposed linker was achieved through a 
FRET based assay. An Oregon Green fluorophore (ex. 488nm, em. 520nm) was coupled to the C-terminal 
benzylic amine forming the donor, while an N-terminal TAMRA fluorophore (ex. 550, em. 575) was 




While the linker within the FRET pair is stable, Oregon Green fluorescence signaling is absent (Fig. 2B-
C). When cleaved, an increase in Oregon Green fluorescence can be monitored over time, which can be 
correlated with a stoichiometric equivalence of payload release, allowing a quantitative measurement of 
linker cleavage over time.  
 
     
Figure 2. Synthetic proposal and chemical basis of a FRET-based assay. A) Synthesis of FRET Pairs. 
Oregon Green is indicated in green, PABC aryl mimic in blue, and TAMRA in orange. B) Cleavage of 
FRET Pair results in Oregon Green release, allowing Oregon Green fluorescence. C) Resistance to 
cleavage maintains the FRET pair, retaining resonance to prevent Oregon green fluorescence.  
2.3 Statement of Purpose 
The goal of this work is to screen a library of peptide linkers using a FRET-based assay to identify linkers 
that surpass stability profile of mcValCitPABC. Screening this library against lysosomal enzymes 
validates a linker’s potential to release a payload effectively intracellularly, while screening against 
known extracellular hydrolases identifies linkers with higher resistance to premature payload release. 
Additionally, monitoring release in serum provides a holistic picture of extracellular stability as opposed 
to individual evaluation of a single enzyme. Herein, we report the synthesis of this FRET library, 
evaluation of linkers against intra and extracellular conditions, identification of linkers with interesting 






3 Results and Discussion 
3.1 Synthesis of FRET Library  
Synthesis of FRET pairs began with the addition of Boc-p-aminobenzyl amine to Oregon Green NHS 
ester (1), and subsequent deprotection to yield the aniline (3). Coupling the aniline (3) to the C-terminus 
of peptides (4) was dependent on the coupling reagents used. Generally, HATU coupling was sufficient 
for amide bond formation, but was found to acylate histidine, forming a 1,1,3,3-tetramethylguanidine 
group on the ε-amine. This undesirable side-product was eliminated by substituting the coupling reagent 
to EDC. In reactions wherein the peptide contained a lysine, the aniline was used in threefold excess in 
order to outcompete intramolecular cyclization. For all conditions, fifteen reactions were performed in 
parallel in 2-dram vials and purified by an automated mass-directed LC/MS. Lastly, Michael addition of 
TAMRA-thiol to the N-terminal maleimide (5) under basic conditions completed the formation of the 
FRET pair (6) (scheme 1). Following this route, a total of 75 FRET pairs were synthesized for evaluation. 
Quenching of Oregon Green fluorescence (typically 50%-80% of the original sample) was observed upon 
addition of the thiol, thus indicating both the success of the Michael addition and energy transfer within 
the FRET pair (Table S1). 
 
Scheme 1. Synthetic scheme of FRET Pairs. (a) Boc-p-aminobenzylamine, DIPEA, DMF, rt. 4 hr. (b) 
TFA, DCM, rt. 1 hr. (c) General Conditions: HATU, HOBt, 2,6-Lutidine, rt. 16 hr. (d) P1, P2 = His: 
EDC, HOBt, 2,6-Lutidine, rt. 16 hr. (e) P2 = Lys: 3 (3 eq.), HATU, HOBt, 2,6-Lutidine, rt. 16 hr. (f) 10% 




3.2 Lysosomal Lability Screening and SAR Relationships of Catabolic Enzymes 
Screening of this synthesized FRET library began with cathepsin B, a known catabolic enzyme of 
ValCitPABC (Fig. 3A).19 Cathepsin B was found to cleave the control ValCit linker with the fastest 
velocity with a large differential between the negative control D-ValD-Cit (Fig. 3B). Most peptides 
falling within this range shared a similar motif within the P2 and P1 positions, with large, hydrophobic 
amino acids occupying the P2 positions (Tyr, Ile). Long aliphatic chains with a hydrogen bond donor (Cit, 
Lys) or small hydrophobic residues (Ala) were permitted in the P2 site. Substrate specificity is comparable 
to previously reported findings on the selectivity filters of cathepsin B.20 
 
Figure 3. Cathepsin B Catabolism Studies. ValCit positive control is indicated in blue, and D-ValD-Cit 
negative control is indicated in red. A. Cathepsin B hydrolysis during 12-hour incubation of FRET pairs 
at 2µg/ml enzyme concentration. B Kinetic plot of positive (ValCit) and negative controls (D-ValD-Cit) 


































































































































































































































































































































































Next we turned to using rat liver trisotomes, lysosomal prep taken from rats, containing a multitude of 
lysosomal enzymes including the previously evaluated cathepsin B. Exposure of the FRET pairs to rat 
liver tritosomes provided a broader, holistic picture of lysosomal cleavage compared to single enzyme 
evaluations (Fig. 4A). As expected, the peptides rapidly cleaved by cathepsin B (Fig. 3A) were shown to 
be cleaved at comparable rates by the tritosomes (Fig. 4A). Unlike the results from the cathepsin B study, 
many linkers exhibited faster rates of cleavage compared to than the ValCit Comparator (Fig. 4A). 
Interestingly, many of the rapidly cleaved linkers shared the structural motif of an asparagine occupying 
the P2 or P1 positions. Furthermore, these linkers were demonstrated the be poorly hydrolyzed by 
cathepsin B, strongly suggesting the presence of a unique protease as a potential vector for enzyme-
mediated drug release. The conserved nature of asparagine residues within the linker pointed to legumain, 
















Figure 4. Rat Liver Tritosomes and Legumain Catabolism Studies. ValCit positive control is indicated in 
blue, and D-ValD-Cit negative control is indicated in red. A. Tritosomal hydrolysis during 6.5-hour 
incubation of FRET pairs at 37.5 µg/ml enzyme concentration. B. Legumain hydrolysis during 12-hour 
incubation of FRET pairs at 5.0 µg/ml enzyme concentration.  
Evaluation of legumain cleavage of this FRET library revealed identical trends between asparagine 
containing linkers and rates of hydrolysis, with P2 asparagine linkers being hydrolyzed more readily than 
P1 asparagine linkers (Fig. 4B). Legumain also was demonstrated to be highly specific for asparagine 
containing linkers, in line with its known catabolic role.21 Interestingly, selectivity filters of legumain 
have been shown to allow asparagine occupation of the S1 site with a versatile S1’ site, enabling legumain 
to generate C-terminal asparagine peptide fragments exclusively.21 This indicates hydrolysis of peptides 
with asparagine in the P2 position results in the release of an undesirable amino acid linked payload (Fig. 








































































































































































































































































































































































































































































































































































































































































before the aniline is possible, but the occupation of the aryl group within the S1’ site may disfavor binding 
to legumain. The removal of the self-immolative PABC spacer would be synthetically efficient for linker 
payload synthesis and may allow release of the unmodified payload at more rapid kinetic rates (Fig. 5B). 
Additionally, the hydrolysis of AsnVal gives hope for the release of MMAE using a terminal Asn linker, 
as MMAE contains an N-methylated valine residue within its structure which would be attached to a 
linker’s C-terminus. Like cathepsin B, legumain has been shown to be upregulated in the tumor 






Figure 5. Illustration of Legumain Cleavage. A) Legumain cleaves resulting in C-terminal asparagine 













3.3 Extracellular Stability Screening and SAR Relationship of Ces1C 
Resistance of linkers to promiscuous extracellular hydrolase Ces1C was performed and revealed 
interesting structural motifs (Fig. 6A). Hydrolysis of tryptophan containing linkers was most rapid, with 
all linkers showing varying degrees of susceptibility. Unexpectedly, P2 citrulline and valine containing 
linkers were the most resistant to cleavage by Ces1C, with the lead linker ValCit showing the most 
impressive resistance. This was surprising considering that multiple papers have demonstrated that 
ValCit-PABC linkers are cleaved by Ces1C.13–16 However, conflicting reports in the literature indicate 
Ces1C cleaves at the C-terminus of the linker, while others report a hydrolysis of the carbamate resulting 
in acylation of the Ces1C catalytic serine.13,14 The lack of a carbamate linkage in our model system may 
rationalize some resistance our library has to Ces1C. The proposed removal PABC through legumain-
mediated release may circumvent this potential of Ces1C hydrolysis at the carbamate linkage. 
Additionally, most attempts to mitigate Ces1C activity on linkers target the P3 position adding unique 
functionalities, where our library contains an unhindered glycine in that position that would not prevent 
Ces1C activity.13,18 Amino acid extension at the C-terminus would allow for an expansive library, shifting 
the current P2 amino acid to the P3 position, allowing us to monitor the impact this site has on linker 
catabolism.  
Stability of linkers within mouse and human serum varied, with more linkers showing instability within 
mouse serum (Fig. 6B, C). ValCit was shown to release 5% and 10% payload over 18 hours in mouse and 
human serum respectively. Tryptophan containing linkers were most readily cleaved in mouse serum, 
likely due to the presence of mouse Ces1C as shown previously. Furthermore, proline and tyrosine in the 
P2 position of linkers showed greater payload release over time. The degree of payload release within 
human serums was much lower but shared the same structural motifs of proline and tyrosine linker 
hydrolysis. In addition, we observed that P2 histidine-containing linkers exhibited relatively high degrees 
of cleavage. Importantly, most asparagine containing linkers, with asparagine occupying both the P1 and 






Figure 6. Stability evaluation of linkers against Ces1C and serum. ValCit positive control is indicated in 
blue, and D-ValD-Cit negative control is indicated in red. Ces1C stability is reported in terms of initial 
velocity of cleavage, and serum stability is reported in terms of percent cleavage. A. Ces1C hydrolysis 
during 10-day incubation of FRET pairs at 10.0µg/ml enzyme concentration. B. Mouse serum stability 


































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































3.4 Identification of Optimal Linker Chemistries for MMAE Linker Payloads 
The rapid hydrolysis of asparagine containing linkers in lysosomes paired with the enhanced stability 
within serum indicates high potential for ADC applications. Linker payload synthesis of identified linkers 
was developed using MMAE as the payload of choice, as its cytotoxic activity is nullified if released in its 
non-native form (Table 1).22 The hypothesis that legumain may not release the unmodified payload 
resulted in the subdivision of asparagine linkers into two groups for future evaluation. Serum stable 
linkers SerAsn, GlnAsn and AsnAsn containing a P1 asparagine are believed to be cleaved at the P1 
position to liberate an unmodified payload, and therefore are hypothesized to be biologically active using 
MMAE. In contrast, the linker AsnAla is shown to be lysosomally labile and extracellularly stable but is 
hypothesized to not be biologically active by releasing a modified, amino acid linked MMAE payload. To 
evaluate the accuracy of our model system in predicting ADC stability and release, TyrTrp was selected 
as a readily hydrolyzed linker in both the lysosome and serum. Conversely, GlnVal was selected as a 
negative control, being resistant to hydrolysis in both the lysosome and serum. 
Table 1. Identified Linkers for MMAE Attachment and Reported Stability Profile 






3-Mal-AEEA-Gly-Val-Cit-PABC-MMAE Yes (Cathepsin B) Yes Active (Positive Control)
3-Mal-AEEA-Gly-Ser-Asn-PABC-MMAE Yes (Legumain) Yes Active 
3-Mal-AEEA-Gly-Tyr-Trp-PABC-MMAE Yes (Cathepsin B) No Active 
3-Mal-AEEA-Gly-Gln-Asn-PABC-MMAE Yes (Legumain) Yes Active 
3-Mal-AEEA-Gly-Gln-Val-PABC-MMAE No Yes Inactive (Negative Control)
3-Mal-AEEA-Gly-Asn-Asn-PABC-MMAE Yes (Legumain) Yes Active 
3-Mal-AEEA-Gly-Asn-Ala-PABC-MMAE Yes (Legumain) Yes Inactive 
 
3.5 Synthesis of MMAE-Linker Payloads 
Identified linkers were taken through a three-step synthesis to attach a PABC spacer and MMAE to each 
linker (scheme 2). Using HATU coupling conditions known to attach Oregon Green, p-aminobenzyl 
alcohol was coupled to the C-terminus of each linker (4). The resulting product (7) was purified by 




situ, followed by substitution using MMAE yielded the final linker payload (9). Material was purified by 
preparative HPLC and characterized by MS and HPLC. Conventional cysteine conjugation to an anti-
Her2 antibody will allow these linker payloads to constitute the final ADCs which will be evaluated for 
cytotoxicity against a breat-cancer cell line at a later date. Attempts to directly attach MMAE to the C-
terminus directly were unsuccessful and will be approached in the future as well.  
 
Scheme 2. Synthetic scheme of MMAE Linker Payloads. (a) HATU, HOBt, 2,6-Lutidine, rt. 2 hr. (b) Bis-
p-nitrophenyl carbonate, DIPEA, 24 hr. (c) MMAE, HOAt, DIPEA, 2,6-Lutidine, rt. 48 hr.   
 
4 Conclusion  
Evaluation of ADC linker stability was successfully performed using a novel FRET-based assay to 
elucidate the stability profiles of various chemical linkers. Linker lability in the presence of lysosomal 
proteases identified a series of asparagine containing linkers, which were identified to be hydrolyzed 
efficiently by the asparagine endopeptidase legumain. The preference of legumain cleavage towards P2 
asparagine linkers alongside the known selectivity of legumain hypothesize that a PABC spacer is poorly 
tolerated by this peptidase. Given the success of cleaving P1 asparagine linkers with legumain, it is 
believed removing the PABC spacer could allow for the direct release of payload alongside being 
synthetically useful in linker payload synthesis.  
Evaluating extracellular stability of these linkers revealed this asparagine series of linkers also retained 
optimal stability within mouse and human serum. Ces1C screening additionally showed most asparagine-
containing linkers to be resistant to this promiscuous hydrolase and identified a structural preference of 




extracellular conditions identified six unique linkers for evaluation in ADC applications. The synthesis of 
linker payloads was performed allowing future conjugation to monoclonal antibodies for ADC evaluation 
of cytotoxicity and ADC stability. Additional directions to pursue include the synthesis of C-terminal 
asparagine coupled MMAE linker payloads for the evaluation of cytotoxicity in the absence of the PABC 
self-immolative spacer. Ultimately, this work has identified a novel vector for enzyme-mediated payload 
release for ADC applications alongside the identification of several linkers with enhanced stability 
profiles that we hope will lead to a new generation of ADC linkers to surpass the limitations of 
ValCitPABC.  
5 Experimental Methods  
5.1 Analytical UPLC/HPLC Methods 
5.1.1 Normal UPLC-MS Method 
Analytical characterization was performed using a Water Acquity H-Class UPLC ® with TUV detector, 
FLR detector, and QDa mass spectrometer. Typically, 1µl injections were separated using an Acquity 
UPLC BEH C18 1.7 µm column (2.1 x 50mm) at 80°C. Eluent was monitored by UV (220 and 254nm), 
fluorescence (ex. 488nm, em. 520nm) and mass spectrometry (150-1250 Da, ES+/ES-). Solvents for the 
mobile phase were water with 0.1% formic acid (solvent A) and acetonitrile (ACN) with 0.1% formic 
acid (solvent B). Flow rate was 0.8 ml/min. Gradient Used: Isocratic solvent B for 0.8 min (0-0.8min), 
then gradient from 10%-95% Solvent B over 4.2 min (0.8-4.5min), isocratic solvent B for 0.3 min (4.5-
4.8min), then gradient from 95% solvent B over 0.1 min (4.8-4.9min), then isocratic solvent B for 0.1 min 
(4.9-5.0min) (Table I).  
Table I. Solvent Gradient of Normal UPLC-MS Method 
Time (min) Flow Rate (ml/min) %A %B 
Initial 0.80 90.0% 10.0% 
0.80 0.80 90.0% 10.0% 
4.50 0.80 10.0% 90.0% 
4.80 0.80 10.0% 90.0% 




5.00 0.80 90.0% 10.0% 
 
5.1.2 Polar UPLC-MS Method 
Analytical characterization of hydrophilic, polar organic compounds was performed using an optimized 
UPLC gradient method. A Waters Acquity H-Class UPLC ® with TUV detector and QDa Mass 
spectrometer was utilized. Typically, 1µl injections were separated using an Acquity UPLC BEH C18 1.7 
µm column (2.1 x 50mm) at 80°C. Eluent was monitored by UV (220 and 254nm), fluorescence (ex. 
488nm, em. 520nm) and mass spectrometry (150-1250 Da, ES+/ES-). Solvents for the mobile phase were 
water with 0.1% formic acid (solvent A) and acetonitrile (ACN) with 0.1% formic acid (solvent B). Flow 
rate was 0.8 ml/min. Gradient Used: Isocratic solvent B for 1.0 min (0-1.0min), then gradient from 3% to 
50% Solvent B over 2.0 min (1.0-3.0min), then gradient from 50% to 95% solvent B over 1.2 min (3.0-
4.2min), then isocratic solvent B for 0.1 min (4.2-4.3min), then gradient from 95% to 3% solvent B for 
0.1 min (4.3-4.4min), then isocratic solvent B for 0.6 min (4.4-5.0min) (Table II).  
Table II. Solvent Gradient for Polar UPLC-MS Method 
Time Flow rate (mL/min) %A %B 
Initial 0.80 97.0% 3.0% 
1.00 0.80 97.0% 3.0% 
3.00 0.80 50.0% 50.0% 
4.20 0.80 5.0%            95.0% 
4.30 0.80 5.0% 95.0% 
4.40 0.80 97.0% 3.0% 
5.00 0.80 97.0% 3.0% 
 
5.1.3 Normal HPLC-MS Method 
Analytical characterization of large (> 1250 Da) organic compounds was performed using a Waters Auto-
purification system containing a 2545 binary gradient module, 2767 sample manager, 2998 UV/PDA 
detector, and SQD2 mass spectrometer. Typically, 1µl injections were separated using an XBridge BEH 
C18 5µm (4.6 x 100 mm) column at 80°C. Eluent was monitored by UV (210-600nm), and mass 
spectrometry (150-1800 Da, ES+/ES-). Solvents for the mobile phase were water with 0.05% formic acid 




Gradient Used: Isocratic solvent B for 1.0 min (0-1.0 min), then gradient from 5% to 99% solvent B over 
2.8 min (1.0-3.8min), then isocratic solvent B for 0.1 min (3.8-3.9min), then gradient from 99% to 5% 
solvent B for 0.1 min (3.9-4.0min), then isocratic solvent B for 1.0 min (4.0-5.0min) (Table III).  
Table III. Solvent Gradient for Normal HPLC-MS Method 
Time Flow rate (mL/min) %A %B 
Initial 2.00 95.0% 5.0% 
1.00 2.00 95.0% 5.0% 
3.80 2.00 1.0% 99.0% 
3.90 2.00 1.0% 99.0% 
4.00 2.00 95.0% 5.0% 
5.00 2.00 95.0% 5.0% 
5.2 Preparative HPLC Methods 
5.2.1 Normal Preparative HPLC Method 
General purification of organic compounds was performed using a Waters Auto-purification system 
containing a 2545 binary gradient module, 2767 sample manager, 2998 UV/PDA detector, and SQD2 
mass spectrometer. Typically, 500µl injections were separated using an XBridge BEH C18 5 μm OBD 
(19 x 100 mm) prep column at room temperature. Eluent was monitored by UV (210-600nm), and mass 
spectrometry (150-2500 Da, ES+/ES-). Solvent for the mobile phase were water with 0.05% 
trifluoroacetic acid (solvent A) and acetonitrile (ACN) with 0.05% trifluoroacetic acid (solvent B). Flow 
rate was 20.0 ml/min. Gradient Used: Isocratic solvent B for 1.0 min (0-1.0min), then gradient from 15% 
to 95% solvent B over 7.0 min (1.0-8.0min), then isocratic solvent B for 0.5 min (8.0-8.5min), then 
gradient from 95% to 15% solvent B for 0.5 min (8.5-9.0min), then isocratic solvent B for 1.0 min (9.0-
10.0min) (Table IV).  
Table IV. Solvent Gradient for Normal Preparative HPLC Method 
Time Flow rate (mL/min) %A %B 
Initial 20.0 85.0% 15.0% 
1.00 20.0 85.0% 15.0% 
8.00 20.0 5.0% 95.0% 
8.50 20.0 5.0%            95.0% 
9.00 20.0 85.0% 15.0% 





5.2.2 Optimized Oregon Green Peptide Preparative HPLC Method 
Purification of Oregon Green coupled linkers was optimized to separate closely eluting materials to 
product UV peaks that appeared under analytical traces. A Waters Auto-purification system containing a 
2545 binary gradient module, 2767 sample manager, 2998 UV/PDA detector, and SQD2 mass 
spectrometer was employed. Typically, 500µl injections were separated using an XBridge BEH C18 5 μm 
OBD (19 x 100 mm) prep column at room temperature. Eluent was monitored by UV (210-600nm), and 
mass spectrometry (150-2500 Da, ES+/ES-). Solvents for the mobile phase were water with 0.05% 
trifluoroacetic acid (solvent A) and acetonitrile (ACN) with 0.05% trifluoroacetic acid (solvent B). Flow 
rate was 20.0 ml/min. Gradient Used: Isocratic solvent B for 1.0 min (0-1.0min), then gradient from 5% 
to 20% solvent B over 0.5 min (1.0-1.5min), then gradient from 20% to 50% solvent B over 7.5 min (1.5-
8.0min), then gradient from 50% to 95% solvent B for 0.5 min (8.0-8.5min), then gradient from 95% to 
5% solvent B for 0.5 min (8.5-9.0min), then isocratic solvent B for 1.0 min (9.0-10.0min) (Table V).  
Table V. Solvent Gradient for Oregon Green Peptide Preparative HPLC Method 
Time Flow rate (mL/min) %A %B 
Initial 20.0 95.0% 5.0% 
1.00 20.0 95.0% 5.0% 
1.50 20.0 80.0% 20.0% 
8.00 20.0 50.0% 50.0% 
8.50 20.0 5.0% 95.0% 
9.00 20.0 95.0% 5.0% 
10.00 20.0 95.0% 5.0% 
 





Oregon Green N-hydroxysuccimide ester (1) (48.7mg, 95.6 µmol, 1 equiv), 4-boc-amino benzylamine 
(34.5mg, 155 µmol, 1.6 equiv), and DIPEA (64mg, 490µmol, 5.1 equiv), was combined in anhydrous 
DMF at a reaction molarity of 50 mM for 4 hours at rt. The resulting 4-boc-aminobenzylamide Oregon 
Green (2) was confirmed through LC/MS (ESI): (M+H)+ 617.2 Da, Retention time 3.47 min. Solution 
was concentrated to dryness over 12 hours. The resulting orange resin was deprotected without an 
intermediate purification step.  
The orange resin (2) (95.6 µmol, 1 equiv) was dissolved into a 20% TFA in DCM solution at a reaction 
molarity of 50 mM for one hour at rt. The resulting p-aminobenzylamide Oregon Green (3) was 
confirmed through Fluorescence (ex. 488, em 520) and LC/MS (ESI): (M+H)+ 517.2 Da, Retention time: 
2.55 min (Figure S1, S2). Solution was concentrated to dryness, then dissolved into DMA for purification 
through the normal preparative HPLC to yield a yellow resin. Total recovery after two steps was 55.7mg 
(88.3 µmol, 92.4%). This yellow resin was again dissolved into DMA to make a 100 mM stock solution 
for future reactions using sub-milligram weights.  
5.4 Synthesis of TAMRA-Mal-AEEA-Gly-P2-P1-p-aminobenzylamide-Oregon Green 
Amide coupling of p-amino benzylamide Oregon Green to the C-terminus of purchased peptide linkers 
(Wuxi®) was dependent on the amino acid residues present. General conditions were used for all peptides 
except those containing lysine or histidine. Optimized conditions for histidine-containing linkers and 
lysine containing linkers are described separately.  
5.4.1 Amide Coupling of PABA-Oregon Green to Mal-AEEA-Gly-P2-P1-OH 
 
All purchased linkers (4) were made into 20mM stock solutions in DMA to measure sub-milligram 




benzylamide Oregon Green (3) (630 µg, 1.00µmol, 1equiv), linker Mal-AEEA-Gly-P2-P1-OH (4) (884 
µg, 1.5µmol, 1.5 equiv) (Table S2), HATU (1.52mg, 4.00 µmol, 4 equiv), HOBt (153 µg, 1.00µmol, 1 
equiv), and 2,6-Lutidine (426 µg, 4.00 µmol, 4 equiv) were combined in sufficient DMA to give a 
reaction molarity of 6.9 mM. The reaction was allowed to stand for 16 hours at rt. Product (5) formation 
was verified by LC/MS and purified by preparative HPLC using the optimized peptide prep method. The 
final amount of purified product (5) was determined using fluorescent quantitation against a standard 
curve prepared with p-amino benzylamide Oregon Green. Analytical characterization (ESI, retention 
time) under the polar UPLC analytical method, and reaction results (purity, yield) are reported in table S2. 
The resulting linker-fluorophores (5) were dissolved into DMA yielding a 50µM Stock solution for future 
use.  
5.4.2 Amide Coupling of PABA-Oregon Green to Mal-AEEA-Gly-His-P1-OH 
 
All purchased linkers (4) were made into 20mM stock solutions in DMA to measure sub-milligram 
quantities and the aniline (3) was previously made into a stock solution for the same reason. p-amino 
benzylamide Oregon Green (470 µg, 0.75 µmol, 1 equiv), linker Mal-AEEA-Gly-His-P1-OH (1.3 mg, 
2.3µmol, 3 equiv) (Table S3), EDC (580 µg, 3.00 µmol, 4 equiv), HOBt (460 µg, 3.00µmol, 4 equiv), and 
2,6-Lutidine (320 µg, 3.00 µmol, 4 equiv) were combined in DMA for a reaction molarity of 4.5 mM for 
16 hours at rt. Product formation was verified by LC/MS and purified through preparative HPLC using 
the optimized peptide prep method. Analytical characterization (ESI, retention time) under the polar 
UPLC analytical method, and reaction results (purity, yield) are reported in table S3. The resulting linker-




5.4.3 Amide Coupling of PABA-Oregon Green to Mal-AEEA-Gly-P2-His-OH 
 
All purchased linkers (4) were made into 20mM stock solutions in DMA to measure sub-milligram 
quantities and the aniline (3) was previously made into a stock solution for the same reason. p-amino 
benzylamide Oregon Green (3) (470 µg, 0.75 µmol, 1 equiv), linker Mal-AEEA-Gly-P2-His-OH (4) (1.3 
mg, 2.3µmol, 3 equiv) (Table S4), EDC (580 µg, 3.00 µmol, 4 equiv), HOBt (460 µg, 3.00µmol, 4 equiv), 
and 2,6-Lutidine (320 µg, 3.00 µmol, 4 equiv) were combined in DMA for a reaction molarity of 4.5 mM 
for 16 hours at rt. Product (5) formation was verified by LC/MS and purified through preparative HPLC 
using the optimized peptide prep method. Analytical characterization (ESI, retention time) under the polar 
UPLC analytical method, and reaction results (purity, yield) are reported in table S4. The resulting linker-
fluorophores (5) were dissolved into DMA yielding a 50µM Stock solution for future use. 
5.4.4 Amide Coupling of PABA-Oregon Green to Mal-AEEA-Gly-P2-Lys-OH 
 
All purchased linkers (4) were made into 20mM stock solutions in DMA to measure sub-milligram 
quantities and the aniline (3) was previously made into a stock solution for the same reason. p-amino 
benzylamide Oregon Green (3) (1.89 mg, 3.00 µmol, 3 equiv), linker Mal-AEEA-Gly-P2-Lys-OH (4) 
(590 µg, 1.0 µmol, 1 equiv) (Table S5), HATU (1.52mg, 4.00 µmol, 4 equiv), HOBt (153 µg, 1.00µmol, 
1 equiv), and 2,6-Lutidine (426 µg, 4.00 µmol, 4 equiv) were combined in DMA for a reaction molarity 
of 6.9 mM for 16 hours at rt. Product (5) formation was verified by LC/MS and purified through 
preparative HPLC using the optimized peptide prep method. Analytical characterization (ESI, retention 




The resulting linker-fluorophores (5) were dissolved into DMA yielding a 50µM Stock solution for future 
use. 
5.4.5 Michael Addition of TAMRA thiol to Mal-AEEA-Gly-P2-P1-PABA-OG  
 
All linker-fluorophores (5) were previously made into 50µM stock solutions in DMA to measure sub-
milligram quantities and TAMRA-thiol was made into a 150µM stock solution in DMA for the purpose 
of the Michael Addition. Mal-AEEA-Gly-P2-P1-PABA-OG (5) (50µl, 2.5 nmol, 1 equiv) and TAMRA 
thiol (50µl, 12.5 nmol, 5 equiv) was combined into a solution of DMA and 50 mM Tris pH 8.5 buffer (aq) 
(10% by volume) for a reaction molarity of 23 µM for 2 hours at rt. The kinetics of the Michael Addition 
were tracked to ensure a complete thiolation of the maleimide was achieved (Fig. 6). Fluorescence of 
Oregon Green was tracked over time to monitor the decrease in fluorescence post-thiol addition. The thiol 
was shown to consume most thiol within the first minute of exposure, with negligible change after one 
hour. Therefore, this reaction was run for two hours to ensure complete consumption of the maleimide.  
 





































Product formation (6) was confirmed quantitatively through the change in Oregon Green fluorescence. 
For each FRET pair prepared in situ, TAMRA-Mal-AEEA-Gly-P2-P1-PABA-OG (6) (4.4µl, 0.10 nmol) 
was diluted in 195.6 µl of 5.6% DMA in NaOAc buffer (pH 5.2) yielding a 200µl, 500 nM solution. For 
each linker, a standard 500nM solution of Mal-AEEA-Gly-P2-P1-PABA-OG (6) was prepared for 
comparison by diluting Mal-AEEA-Gly-P2-P1-PABA-OG (6) (2.0µl, 0.10 nmol) into 198.0µl of 6.7% 
DMA in NaOAc buffer (pH 5.2). Fluorescence of Oregon Green within TAMRA-Mal-AEEA-Gly-P2-P1-
PABA-OG (6) and the control Mal-AEEA-Gly-P2-P1-PABA-OG (5) was measured at excitation 488nm 
and emission 520nm and the concentration of Oregon Green was back-calculated using a linear standard 
curve. Percent difference in fluorescence is reported in table S1.  
5.5 Synthesis of Mal-AEEA-Gly-P2-P1-PABC-MMAE Linker Payloads 
5.5.1 Amide Coupling of p-amino benzyl alcohol to Mal-AEEA-Gly-P2-P1-OH 
 
Mal-AEEA-Gly-P1-P2-OH (4) (8.35 mg, 15.0 µmol, 1 equiv), p-aminobenzyl alcohol (2.77mg, 
22.5µmol, 1.5 equiv), HATU (22.8mg, 60.0 µmol, 4 equiv), HOBt (2.30 mg, 15.0 µmol, 1 equiv), and 
2,6-Lutidine (6.4mg, 60.0µmol, 4 equiv) were combined in DMA for a reaction molarity of 13.0 mM for 
2 hours at rt. Product (7) formation was verified by LC/MS, and purified through the optimized peptide 
prep method. Resulting alcohols (7) were green resins. Analytical characterization (ESI, retention time) 






5.5.2 Activation of Benzyl Alcohol with Bis-p-nitrophenyl Carbonate 
 
Mal-AEEA-Gly-P1-P2-PAB-OH (7) (Table S8, 1 equiv), bis-p-nitrophenyl carbonate (Table S9, 1.75 
equiv), and DIPEA (Table S9, 1.5 equiv) were combined in anhydrous DMF for 24 hours at rt. Product 
(8) formation was verified by LC/MS using the normal UPLC analytical method (Table S7). The material 
was moved forward without a purification step.  
5.5.3 Substitution of p-nitrophenyl with Monomethyl Auristatin E (MMAE) 
 
Mal-AEEA-Gly-P1-P2-PABC-PNP (8) (Table S10, 1 equiv), MMAE (Table S10, 2 equiv), HOAt (Table 
S10, 1 equiv), 2,6-Lutidine (Table S10, 2 equiv), and DIPEA (Table S10, 3 equiv) were combined in the 
anhydrous DMF of the previous reaction, and left at rt for 48 hours. Product (9) formation was verified by 
LC/MS and purified by preparative HPLC using the normal preparative method. Resulting products were 
a clear resin. Analytical characterization (ESI, retention time) under the normal HPLC analytical method 
and reaction results (purity, total yield over two steps) are reported on table S8.  
5.6 In vitro Enzymatic Stability Assays 
5.6.1 Cathepsin B Stability Assay 
Human Liver Cathepsin B was purchased from MilliporeSigma. Cathepsin B was activated using DTT by 
combining 67.5µl of cathepsin B (1mg/ml) with 67.5µl of DTT (50mM) in NaOAc (0.2M, pH 5.2) and 
heating the solution at 37°C for 20 minutes. Activated cathepsin B (0.5 mg/ml) was diluted using 240µl 
of NaOAc (0.2M, pH 5.2) yielding an 80 µg/ml enzyme concentration. FRET pairs prepared in situ were 




DMA in NaOAc buffer (0.2M, pH 5.2) and activated cathepsin B (5µl, 400 ng) for a final linker 
concentration of 500nM and final enzyme concentration of 2 µg/ml in Aqueous 7.5% DMA in NaOAc 
(0.2M, pH 5.2) buffer. The assay was performed in a 96-well plate format at ambient temperature. 
Change in Oregon Green fluorescence was measured at excitation 488nm and emission 520nm over 12 
hours taking a timepoint every 10 minutes. Data analysis is described below. 
5.6.2 Tritosomal Stability Assay 
Rat liver tritosomes were purchased from XenoTech. Tritosomes were activated using DTT by combining 
230µl of tritosomes (2.5mg/ml) with 230µl of DTT (50mM) in NaOAc (0.2M, pH 4.7) and heating the 
solution at 37°C for 30 minutes. Activated tritosomes (1.25 mg/ml) were diluted using 1070µl of NaOAc 
(0.2M, pH 4.7) yielding a 375 µg/ml enzyme concentration. FRET pairs prepared in situ were plated in a 
96-well plate by combining TAMRA-Mal-AEEA-Gly-P2-P1-PABA-OG (6) (4.4µl 0.10 nmol), 175.6µl 
of 5.75% DMA in NaOAc buffer (0.2M, pH 4.7) and activated tritosomes (20µl, 7.50 µg) for a final 
linker concentration of 500nM and final enzyme concentration of 37.5 µg/ml in Aqueous 7.5% DMA in 
NaOAc (0.2M, pH 4.7) buffer. The assay was performed in a 96-well plate format at ambient 
temperature. Change in Oregon Green fluorescence was measured at excitation 488nm and emission 
520nm over 6.5 hours taking a timepoint every 10 minutes using a Molecular Devices i3x Microplate 
Reader. Data analysis is described below.  
5.6.3 Legumain Stability Assay  
Recombinant human legumain was purchased from Novoprotein Scientific. Legumain was activated 
using DTT by combining 43µl of tritosomes (1.0mg/ml) with 43µl of DTT (50mM) in NaOAc (0.2M, pH 
4.7) and heating the solution at 37°C for 30 minutes. Activated legumain (0.50 mg/ml) was diluted using 
730µl of NaOAc(0.2M, pH 4.7)  yielding a 50 µg/ml enzyme concentration. FRET pairs prepared in situ 
were plated in a 96-well plate by combining TAMRA-Mal-AEEA-Gly-P2-P1-PABA-OG (6) (2.2µl, 0.5 
nmol), 87.8µl of NaOAc buffer (pH 4.7) and activated legumain (10µl, 500 ng) for a linker concentration 




assay was performed in a 96-well plate format at ambient temperature. Change in Oregon Green 
fluorescence was measured at excitation 488nm and emission 520nm over 12 hours taking a timepoint 
every 10 minutes using a Molecular Devices i3x Microplate Reader. Data analysis is described below. 
5.6.4 Carboxyesterase 1C Stability Assay  
Recombinant mouse carboxyesterase 1C was purchased from MyBioSource. Enzyme was prepared by 
diluting 80.5µl of Ces1C (1 mg/ml) with 724.5 µl of PBS (0.01M, pH 7.4) yielding a 100 µg/ml enzyme 
concentration. FRET pairs were prepared in situ were plated in a 96-well plate by combining TAMRA-
Mal-AEEA-Gly-P2-P1-PABA-OG (6) (2.2µl, 0.05 nmol), 87.8µl of PBS buffer (0.01M, pH 7.4) and 
Ces1C (10µl, 1.0 µg) for a final linker concentration of 500 nM and final enzyme concentration of 10 
µg/ml in Aqueous 2.0% DMA in PBS (0.01M, pH 7.4) buffer. The assay was performed in a 96-well 
plate format at 37°C. Change in Oregon Green fluorescence was measured at excitation 488nm and 
emission 520nm over 10 days taking a timepoint once every 24 hours using a Molecular Devices i3x 
Microplate Reader. Data analysis is described below. 
5.6.5 Quantitative Analysis of Single Enzyme FRET Pair Hydrolysis 
5.6.5.1 Calculating Percent Cleavage of the Peptide Linker 
Cathepsin B, tritosomes, legumain and Ces1C activity on each peptide linker was evaluated by calculating 
the final percent cleavage of each linker. Fluorescence readings were converted to molarity through a 
linear Oregon Green standard curve spanning 7.8 nM to 1000 nM, a subsection of the shown linear range 
(Fig. 8). Taking the initial and final timepoint, percent cleavage was calculated through the following 
equation: 
𝑃𝑒𝑟𝑐𝑒𝑛𝑡 𝐶𝑙𝑒𝑎𝑣𝑎𝑔𝑒  
𝐹𝑖𝑛𝑎𝑙 𝑀𝑜𝑙𝑎𝑟𝑖𝑡𝑦 𝐼𝑛𝑖𝑡𝑖𝑎𝑙 𝑀𝑜𝑙𝑎𝑟𝑖𝑡𝑦








Figure 8. Oregon Green fluorescent Standard curves. Double log was taken to show linearity from 128pM 
to 50µM. A) Fluorescence of Oregon Green over 128pM to 50µM. R = 0.9675 B) Linear portion of figure 
8A. Linearity was shown to range from 3.2nM to 10µM. R = 0.9989 
 
5.6.5.2 Calculating Enzymatic Velocity of Peptide Linker Hydrolysis 
Cathepsin B, tritosomes, legumain and Ces1C activity on each peptide linker was evaluated by calculating 
the initial enzymatic velocity. Initial enzymatic velocity was calculated by taking the derivative of the 
linear region of the plot moles of Oregon green vs. time. This linear region was found to be the first 10% 
of cleavage for peptides of positive velocities under all enzymatic conditions. For a peptide exceeding 
10% cleavage, the slope of the linear region was calculated from time zero until the timepoint exceeding 
10% cleavage. For a peptide less than 10% cleavage, the slope of was calculated for all timepoints. 
Correlation coefficients (R) were calculated for each regression to verify linearity (Table S11).  
5.7 In vitro Serum Stability Assays 
5.7.1 Mouse Serum Stability Assay 
Mouse serum was purchased from Equitech-Bio. Mouse serum was prepared through filter sterilization 
and followed by combining penicillin (100µl, 100 units) with mouse serum (10 ml). FRET pairs prepared 


























































of sterile mouse serum for a linker concentration of 500 nM and DMA percent volume of 2.0%. Change 
in Oregon Green fluorescence was measured at excitation 488nm and emission 520nm over 18 hours 
taking a timepoint once every 10 minutes using a Molecular Devices i3x Microplate Reader. Data 
analysis is described below.    
5.7.2 Human Serum Stability Assay 
Human serum was purchased from MP Biomedicals. Human serum was prepared through filter 
sterilization by combining penicillin (100µl, 100 units) with human serum (10 ml). FRET pairs prepared 
in situ were plated by plating TAMRA-Mal-AEEA-Gly-P2-P1-PABA-OG (6) (4.4 µl 0.10 nmol), 195.4µl 
of sterile human serum for a linker concentration of 500 nM and DMA percent volume of 2.0%. Change 
in Oregon Green fluorescence was measured at excitation 488nm and emission 520nm over 18 hours 
taking a timepoint once every 10 minutes using a Molecular Devices i3x Microplate Reader. Data 
analysis is described below.    
5.7.3 Quantitative Analysis of Linker Serum Stability 
Activity of enzymes on each peptide linker within mouse and human serum was evaluated by calculating 
the final percent cleavage of each linker. Fluorescence readings were converted to molarity through a 
linear Oregon Green Standard curve spanning 7.8 nM to 1000 nM (Fig. 8). Taking the initial and final 
timepoint, percent cleavage was calculated through the following equation: 
𝑃𝑒𝑟𝑐𝑒𝑛𝑡 𝐶𝑙𝑒𝑎𝑣𝑎𝑔𝑒  
𝐹𝑖𝑛𝑎𝑙 𝑀𝑜𝑙𝑎𝑟𝑖𝑡𝑦 𝐼𝑛𝑖𝑡𝑖𝑎𝑙 𝑀𝑜𝑙𝑎𝑟𝑖𝑡𝑦









6 Supplemental Material 
6.1 Percent Oregon Green Signal Quenching of FRET Pairs 
 
Table S1. Percent Oregon Green Fluorescence Signal Quenching of FRET Pairs upon addition of the 
TAMRA-thiol.  

























































































6.2 Analytical Characterization of Organic Compounds 
 
 
Figure S1. Analytical Characterization of Modified Oregon Green Fluorophore. Fluorescence (ex. 488nm, 
em. 520nm), UV absorbance at 220 and 254nm, and mass spectrometry of Purified fluorophore are 
displayed.  
 
Figure S2. Mass spectrometry of Modified Oregon Green Fluorophore (m.w. = 516.2 Da) 
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JM426-Dry (3) ACQUITY FLR ChA Ex488,Em525 nm
Range: 38604392.46


































Table S2. Analytical Characterization and Reaction Results of Mal-AEEA-Gly-P2-P1-p-aminobenzyl 
amide Oregon Green Synthesis.  












3-Mal-AEEA-Gly-Val-Cit-PABA-OG 1126.53 2.91 0.072 6.41 >99% 
3-Mal-AEEA-Gly-D-Val-D-Cit-
PABA-OG 1126.56 2.90 0.156 13.79 >99% 
3-Mal-AEEA-Gly-Ala-Ala-PABA-OG 1012.43 2.88 0.186 18.38 >99% 
3-Mal-AEEA-Gly-Gly-Gly-PABA-OG 984‐.39 2.80 0.247 20.60 >95% 
3-Mal-AEEA-Gly-Gly-Asn-PABA-OG 1041.47 2.75 0.062 4.85 >99% 
3-Mal-AEEA-Gly-Gly-Aib-PABA-OG 1012.40 2.88 0.044 3.56 ~60% 
3-Mal-AEEA-Gly-Gly-1nal-PABA-OG 1124.48 3.28 0.213 15.52 >99% 
3-Mal-AEEA-Gly-Gly-2nal-PABA-OG 1124.51 3.30 0.163 11.92 >99% 
3-Mal-AEEA-Gly-Gly-Phe-PABA-OG 1074.52 3.11 0.131 10.03 ~65% 
3-Mal-AEEA-Gly-Gly-Val-PABA-OG 1026.49 3.00 0.121 9.71 ~65% 
3-Mal-AEEA-Gly-Gly-Cit-PABA-OG 1084.47 2.76 0.133 10.05 ~75% 
3-Mal-AEEA-Gly-Gly-Trp-PABA-OG 1113.51 3.11 0.084 6.19 ~80% 
3-Mal-AEEA-Gly-Ser-Asn-PABA-OG 1071.45 2.75 0.126 9.65 >99% 
3-Mal-AEEA-Gly-Ser-Aib-PABA-OG 1042.46 2.86 0.167 13.20 >99% 
3-Mal-AEEA-Gly-Ser-Phe-PABA-OG 1104.55 3.10 0.547 40.73 >95% 
3-Mal-AEEA-Gly-Ser-Ala-PABA-OG 1028.44 2.83 0.273 21.78 >99% 
3-Mal-AEEA-Gly-Ser-Val-PABA-OG 1056.53 2.96 0.366 28.48 >99% 
3-Mal-AEEA-Gly-Ser-Cit-PABA-OG 1114.55 2.75 0.266 19.58 >99% 
3-Mal-AEEA-Gly-Ser-Trp-PABA-OG 1143.52 3.09 0.312 22.42 >99% 
3-Mal-AEEA-Gly-Pro-Asn-PABA-OG 1081.50 2.81 0.171 12.97 >92% 
3-Mal-AEEA-Gly-Pro-Aib-PABA-OG 1052.51 2.86 0.149 11.66 >60% 
3-Mal-AEEA-Gly-Pro-Phe-PABA-OG 1114.54 3.21 0.367 27.05 >95% 
3-Mal-AEEA-Gly-Pro-Ala-PABA-OG 1038.46 2.91 0.389 30.79 >92% 
3-Mal-AEEA-Gly-Pro-Val-PABA-OG 1066.50 3.06 0.361 27.80 >99% 
3-Mal-AEEA-Gly-Pro-Cit-PABA-OG 1124.53 2.83 0.290 21.21 >92% 
3-Mal-AEEA-Gly-Pro-Trp-PABA-OG 1153.50 3.18 0.245 17.43 >99% 
3-Mal-AEEA-Gly-Tyr-Asn-PABA-OG 1147.48 2.85 0.164 11.75 >99% 
3-Mal-AEEA-Gly-Tyr-Aib-PABA-OG 1118.51 3.00 0.072 5.29 >99% 
3-Mal-AEEA-Gly-Tyr-Phe-PABA-OG 1180.50 3.20 0.282 19.63 >90% 
3-Mal-AEEA-Gly-Tyr-Ala-PABA-OG 1104.48 2.95 0.320 23.82 >99% 
3-Mal-AEEA-Gly-Tyr-Val-PABA-OG 1132.53 3.06 0.241 17.46 >90% 
3-Mal-AEEA-Gly-Tyr-Cit-PABA-OG 1190.91 2.86 0.256 17.67 >90% 
3-Mal-AEEA-Gly-Tyr-Trp-PABA-OG 1219.45 3.18 0.195 13.15 >99% 
3-Mal-AEEA-Gly-Gln-Asn-PABA-OG 1112.54 2.73 0.130 9.57 >99% 
3-Mal-AEEA-Gly-Gln-Aib-PABA-OG 1083.51 2.85 0.099 7.54 >95% 
3-Mal-AEEA-Gly-Gln-Phe-PABA-OG 1145.52 3.06 0.305 21.87 >99% 
3-Mal-AEEA-Gly-Gln-Ala-PABA-OG 1069.45 2.81 0.471 36.16 >92% 
3-Mal-AEEA-Gly-Gln-Val-PABA-OG 1097.52 2.93 0.449 33.63 >80% 
3-Mal-AEEA-Gly-Gln-Cit-PABA-OG 1155.48 2.73 0.287 20.40 >99% 
3-Mal-AEEA-Gly-Gln-Trp-PABA-OG 1184.46 3.06 0.072 5.02 >99% 




3-Mal-AEEA-Gly-Ile-Aib-PABA-OG 1068.57 3.13 0.114 11.13 >99% 
3-Mal-AEEA-Gly-Ile-Phe-PABA-OG 1130.57 3.33 0.240 17.44 >95% 
3-Mal-AEEA-Gly-Ile-Ala-PABA-OG 1054.48 3.06 0.293 22.82 >99% 
3-Mal-AEEA-Gly-Ile-Val-PABA-OG 1082.55 3.20 0.236 17.89 >99% 
3-Mal-AEEA-Gly-Ile-Cit-PABA-OG 1140.51 2.96 0.163 11.71 >99% 
3-Mal-AEEA-Gly-Ile-Trp-PABA-OG 1169.53 3.30 0.140 9.81 >99% 
3-Mal-AEEA-Gly-Asn-Asn-PABA-OG 1098.47 2.73 0.165 12.32 >99% 
3-Mal-AEEA-Gly-Asn-Aib-PABA-OG 1069.46 2.83 0.188 14.45 >95% 
3-Mal-AEEA-Gly-Asn-Phe-PABA-OG 1131.49 3.05 0.348 25.24 >99% 
3-Mal-AEEA-Gly-Asn-Ala-PABA-OG 1055.53 2.81 0.200 15.61 >85% 
3-Mal-AEEA-Gly-Asn-Val-PABA-OG 1083.51 2.93 0.218 16.52 >99% 
3-Mal-AEEA-Gly-Asn-Cit-PABA-OG 1141.46 2.73 0.536 38.60 >99% 
3-Mal-AEEA-Gly-Asn-Trp-PABA-OG 1170.50 3.05 0.218 15.32 >99% 
 
Table S3. Analytical Characterization and Reaction Results of Mal-AEEA-Gly-His-P1-p-aminobenzyl 
amide Oregon Green Synthesis.  












3-Mal-AEEA-Gly-His-Asn-PABA-OG 1121.53 2.48 0.152 14.83 >99% 
3-Mal-AEEA-Gly-His-Aib-PABA-OG 1092.53 2.56 0.037 3.68 >99% 
3-Mal-AEEA-Gly-His-Phe-PABA-OG 1154.51 2.75 0.048 4.52 >99% 
3-Mal-AEEA-Gly-His-Ala-PABA-OG 1078.51 2.55 0.058 5.90 >99% 
3-Mal-AEEA-Gly-His-Val-PABA-OG 1106.53 2.85 0.042 4.20 >99% 
3-Mal-AEEA-Gly-His-Cit-PABA-OG 1164.55 2.48 0.031 2.92 >99% 
3-Mal-AEEA-Gly-His-Trp-PABA-OG 1193.50 2.76 0.039 3.58 >99% 
 
Table S4. Analytical Characterization and Reaction Results of Mal-AEEA-Gly-P2-His- p-aminobenzyl 
amide Oregon Green Synthesis.  












3-Mal-AEEA-Gly-Gly-His-PABA-OG 1064.50 2.50 0.137 10.54 >99% 
3-Mal-AEEA-Gly-Ser-His-PABA-OG 1094.53 2.50 0.082 8.47 >99% 
3-Mal-AEEA-Gly-Pro-His-PABA-OG 1104.47 2.55 0.182 18.18 >99% 
3-Mal-AEEA-Gly-Tyr-His-PABA-OG 1170.50 2.58 0.144 14.28 >99% 
3-Mal-AEEA-Gly-Gln-His-PABA-OG 1135.51 2.48 0.213 19.97 >99% 
3-Mal-AEEA-Gly-Ile-His-PABA-OG 1120.53 2.66 0.102 9.86 >99% 








Table S5. Analytical Characterization and Reaction Results of Mal-AEEA-Gly-P2-Lys- p-aminobenzyl 
amide Oregon Green Synthesis.  












3-Mal-AEEA-Gly-Gly-Lys-PABA-OG 1055.55 2.50 0.120 9.30 >99% 
3-Mal-AEEA-Gly-Ser-Lys-PABA-OG 1085.61 2.50 0.009 0.70 >70% 
3-Mal-AEEA-Gly-Pro-Lys-PABA-OG 1095.59 2.55 0.102 7.64 >99% 
3-Mal-AEEA-Gly-Tyr-Lys-PABA-OG 1161.11 2.51 0.338 23.93 >50% 
3-Mal-AEEA-Gly-Gln-Lys-PABA-OG 1126.52 2.46 0.137 9.99 >99% 
3-Mal-AEEA-Gly-Ile-Lys-PABA-OG 1111.58 2.70 0.208 15.36 >60% 
3-Mal-AEEA-Gly-Asn-Lys-PABA-OG 1112.56 2.46 0.164 12.14 >99% 
 
Table S6. Analytical Characterization and Reaction Results of Mal-AEEA-Gly-P2-P1-PAB-OH Synthesis.  












3-Mal-AEEA-Gly-Val-Cit-PAB-OH 733.3 2.36 9.5 86.4 >99% 
3-Mal-AEEA-Gly-Ser-Asn-PAB-OH 678.3 2.07 5.9 58.1 >99% 
3-Mal-AEEA-Gly-Tyr-Trp-PAB-OH 826.3 2.79 9.7 78.4 >99% 
3-Mal-AEEA-Gly-Gln-Asn-PAB-OH 719.2 2.08 7.4 68.7 >99% 
3-Mal-AEEA-Gly-Gln-Val-PAB-OH 704.3 2.42 9.2 87.2 >99% 
3-Mal-AEEA-Gly-Asn-Asn-PAB-OH 705.3 2.05 8.5 80.4 >99% 
3-Mal-AEEA-Gly-Asn-Ala-PAB-OH 662.3 2.18 5.5 55.4 >99% 
 
Table S7. Analytical Characterization and Results of Mal-AEEA-Gly-P2-P1-PABC-PNP Synthesis 
Product Linker Chemistry                   
(3-Mal-AEEA-Gly-P2-P1-PABC-PNP) 






3-Mal-AEEA-Gly-Val-Cit-PABC-PNP 898.3 2.74 11.6 13.0 
3-Mal-AEEA-Gly-Ser-Asn-PABC-PNP 843.2 2.45 7.3 8.7 
3-Mal-AEEA-Gly-Tyr-Trp-PABC-PNP 991.3 2.99 11.6 11.8 
3-Mal-AEEA-Gly-Gln-Asn-PABC-PNP 884.3 2.45 9.1 10.3 
3-Mal-AEEA-Gly-Gln-Val-PABC-PNP 869.3 2.78 11.4 13.1 
3-Mal-AEEA-Gly-Asn-Asn-PABC-PNP 870.2 2.44 10.5 12.1 
3-Mal-AEEA-Gly-Asn-Ala-PABC-PNP 827.3 2.59 6.9 8.3 
 
Table S8. Analytical Characterization and Results of Mal-AEEA-Gly-P2-P1-PABC-MMAE Synthesis.  












3-Mal-AEEA-Gly-Val-Cit-PABC-MMAE 1477.4 3.41 1.1 5.7 > 99% 
3-Mal-AEEA-Gly-Ser-Asn-PABC-MMAE 1422.4 3.40 0.8 6.5 < 50% 
3-Mal-AEEA-Gly-Tyr-Trp-PABC-MMAE 1570.5 3.57 1.7 9.2 >93% 
3-Mal-AEEA-Gly-Gln-Asn-PABC-MMAE 1463.5 3.31 2.9 19.2 > 99% 
3-Mal-AEEA-Gly-Gln-Val-PABC-MMAE 1448.4 3.45 1.7 9.0 > 99% 




3-Mal-AEEA-Gly-Asn-Ala-PABC-MMAE 1406.4 3.38 2.3 19.7 > 99% 
 
6.3 Reaction Conditions of MMAE Linker Payload Synthesis 
 
Table S9. Reaction Conditions and Results of Mal-AEEA-Gly-P2-P1-PABC-PNP Synthesis.  












3-Mal-AEEA-Gly-Val-Cit-PABC-PNP 6.90 21.4 2.5 19.5 
3-Mal-AEEA-Gly-Ser-Asn-PABC-PNP 4.63 13.5 1.7 13.1 
3-Mal-AEEA-Gly-Tyr-Trp-PABC-PNP 6.25 19.4 2.3 17.6 
3-Mal-AEEA-Gly-Gln-Asn-PABC-PNP 5.48 16.1 2.0 15.5 
3-Mal-AEEA-Gly-Gln-Val-PABC-PNP 6.96 24.7 2.5 19.6 
3-Mal-AEEA-Gly-Asn-Asn-PABC-PNP 6.42 20.7 2.3 18.1 
3-Mal-AEEA-Gly-Asn-Ala-PABC-PNP 4.43 14.8 1.6 12.5 
 
Table S10. Reaction Conditions of Mal-AEEA-Gly-P2-P1-PABC-MMAE Synthesis.  










3-Mal-AEEA-Gly-Val-Cit-MMAE 17.20 24.0 1.8 13.0 
3-Mal-AEEA-Gly-Ser-Asn-MMAE 10.93 15.2 1.2 8.7 
3-Mal-AEEA-Gly-Tyr-Trp-PABC-MMAE 15.61 21.8 1.6 11.8 
3-Mal-AEEA-Gly-Gln-Asn-PABC-MMAE 13.04 18.2 1.4 10.3 
3-Mal-AEEA-Gly-Gln-Val-PABC-MMAE 19.58 27.3 1.8 13.1 
3-Mal-AEEA-Gly-Asn-Asn-PABC-MMAE 16.60 23.1 1.6 12.1 
3-Mal-AEEA-Gly-Asn-Ala-PABC-MMAE 11.81 16.5 1.1 8.3 












3-Mal-AEEA-Gly-Val-Cit-PABC-MMAE 5.0 38.9 2.8 25.9 
3-Mal-AEEA-Gly-Ser-Asn-PABC-MMAE 3.4 26.1 1.9 17.4 
3-Mal-AEEA-Gly-Tyr-Trp-PABC-MMAE 4.6 35.3 2.5 23.5 
3-Mal-AEEA-Gly-Gln-Asn-PABC-MMAE 4.0 30.9 2.2 20.6 
3-Mal-AEEA-Gly-Gln-Val-PABC-MMAE 5.1 39.2 2.8 26.2 
3-Mal-AEEA-Gly-Asn-Asn-PABC-MMAE 4.7 36.2 2.6 24.1 









6.4 Regression Analysis of Initial Enzymatic Velocities 
 
Table S11. Initial Enzymatic Velocities and Regression Analysis of Catabolic Enzymes against Linkers  













ValCit 5.82E-05 0.999 6.62E-05 0.999 8.39E-07 0.959 1.78E-05 0.936
D-Val-D-Cit 5.69E-06 0.962 8.82E-06 0.949 1.19E-06 0.906 2.22E-05 0.980
AlaAla 2.76E-05 0.977 2.64E-05 0.949 2.01E-06 0.849 3.83E-05 0.974
GlyGly 6.35E-06 0.986 8.69E-06 0.943 1.39E-06 0.904 0.000193 0.999
GlyAsn 8.66E-06 0.989 1.26E-05 0.947 1.06E-06 0.790 0.000147 1.000
GlyAib 1.06E-05 0.966 1.3E-05 0.893 1.81E-06 0.836 0.000124 0.994
Gly1nal 7.69E-06 0.985 8.34E-06 0.933 2.94E-06 0.862 0.00019 0.998
Gly2nal 7.97E-06 0.986 7.11E-06 0.916 2.94E-06 0.826 0.000226 0.979
GlyPhe 7.58E-06 0.926 1.26E-05 0.850 1.29E-05 0.931 0.000121 1.000
GlyHis 4.52E-06 0.975 6.71E-06 0.904 6.25E-07 0.797 3.39E-05 0.939
GlyVal 9.22E-06 0.906 1.35E-05 0.871 2.36E-06 0.797 9.26E-05 0.980
GlyLys 1.42E-05 0.941 3.92E-05 0.965 8.59E-07 0.618 -4.7E-06 -0.300
GlyCit 1.03E-05 0.941 1.25E-05 0.866 2.09E-06 0.791 7.75E-05 0.964
GlyTrp 6.74E-06 0.873 4.47E-06 0.515 2.5E-06 0.619 2.04E-05 0.928
SerAsn 3.53E-06 0.968 4.32E-05 0.998 1.02E-05 0.994 7.73E-05 0.989
SerAib 1.88E-06 0.932 3.28E-06 0.867 3.52E-07 0.572 6.32E-05 0.996
SerPhe 1.86E-06 0.886 2.75E-06 0.637 9.99E-07 0.813 2.84E-05 0.982
SerHis -9.6E-07 -0.292 -2.5E-06 -0.558 1.15E-06 0.917 4.53E-05 0.947
SerAla 1.07E-05 0.996 6.77E-06 0.895 8.19E-07 0.906 7.16E-05 0.963
SerVal 6.08E-07 0.418 1.19E-06 0.396 5.44E-07 0.873 3.32E-05 0.986
SerLys -2.7E-06 -0.388 -6.7E-06 -0.650 6.16E-07 0.525 2.59E-05 0.972
SerCit 7.94E-06 0.993 8.21E-06 0.958 5.84E-07 0.889 5.93E-05 0.990
SerTrp 6.76E-06 0.994 5.12E-06 0.951 7.33E-07 0.941 0.000272 1.000
ProAsn 4.36E-06 0.990 9.28E-06 0.944 1.21E-06 0.945 6.76E-05 0.998
ProAib 2.52E-06 0.826 6.54E-06 0.880 3.36E-07 0.685 3.77E-05 0.975
ProPhe 2.25E-06 0.957 2.88E-06 0.734 1.07E-06 0.899 5.24E-05 0.964
ProHis 1.92E-06 0.912 2.74E-06 0.763 8.07E-07 0.953 6.92E-05 0.950
ProAla 2.61E-06 0.948 3.31E-06 0.782 6.01E-07 0.917 4.34E-05 0.986
ProVal 2.72E-07 0.315 1.95E-06 0.736 4.9E-07 0.844 3.09E-05 0.984
ProLys 4.16E-07 0.307 -1.5E-06 -0.448 9.62E-07 0.921 4.74E-05 0.981
ProCit 1.14E-06 0.805 2.55E-06 0.728 8.08E-07 0.925 3.38E-05 0.980
ProTrp 3.45E-06 0.958 6.79E-06 0.941 1.46E-06 0.939 0.000398 1.000
HisAsn 5.87E-07 0.589 3.32E-06 0.861 1.36E-06 0.980 5.39E-05 0.994
HisAib 3.45E-07 0.395 5.03E-07 0.196 7.02E-07 0.880 5.43E-05 0.989
HisPhe 1.97E-06 0.877 1.02E-06 0.272 1.7E-06 0.891 4.04E-05 0.973
HisAla 7.55E-06 0.990 5.69E-06 0.860 7.16E-07 0.905 2.52E-05 0.930
HisVal 4.74E-06 0.986 4.65E-06 0.837 1.54E-06 0.894 2.28E-05 0.948
HisCit 3.01E-06 0.967 3.87E-07 0.157 7.62E-07 0.928 1.39E-05 0.967
HisTrp 2.76E-06 0.937 1.21E-06 0.407 1.39E-06 0.858 0.000198 1.000




TyrAib 3.82E-07 0.445 2.01E-06 0.613 7.64E-07 0.848 8.49E-05 0.994
TyrPhe 4.61E-06 0.989 8.16E-05 0.999 1.67E-06 0.856 4.66E-05 0.981
TyrPhe 7.3E-06 0.973 2.14E-05 0.984 1.21E-06 0.880 3.77E-05 0.969
TyrAla 4.15E-05 0.999 5.54E-05 0.996 6.89E-07 0.870 3.53E-05 0.985
TyrVal -1E-06 -0.557 6.34E-06 0.853 9.01E-07 0.885 2.13E-05 0.970
TyrLys 1.86E-06 0.420 3.65E-06 0.374 9.67E-07 0.614 7.85E-06 0.965
TyrCit 2.91E-05 0.995 5.34E-05 0.996 8.63E-07 0.906 2.76E-05 0.983
TyrTrp 1.77E-05 0.997 0.000164 0.999 1.52E-06 0.925 0.000476 1.000
GlnAsn 4.47E-06 0.970 2.13E-05 0.997 5.45E-06 0.992 5.73E-05 0.995
GlnAib 1.46E-06 0.881 2.31E-06 0.707 8.15E-07 0.936 7E-05 0.997
GlnPhe 2.39E-06 0.919 4.68E-06 0.883 9.27E-07 0.889 4.16E-05 0.994
GlnHis 1.72E-06 0.909 2.38E-06 0.728 9.47E-07 0.938 5.83E-05 0.956
GlnAla 8.25E-07 0.392 -1.8E-07 -0.041 5.1E-07 0.831 3.74E-05 0.964
GlnVal -4.9E-06 -0.911 -4.3E-06 -0.736 9.99E-07 0.896 1.41E-05 0.969
GlnLys -1E-05 -0.877 -1.8E-05 -0.938 1.84E-06 0.829 4.75E-05 0.966
GlnCit 2.99E-06 0.920 5.95E-06 0.787 7.69E-07 0.891 3.15E-05 0.982
GlnTrp 3.72E-06 0.971 6.07E-06 0.949 1.11E-06 0.972 9.25E-05 0.935
IleAsn 6.33E-06 0.985 4.19E-05 0.996 1.3E-05 0.986 8.27E-05 0.998
IleAib 2.19E-06 0.881 5.65E-06 0.945 6.39E-07 0.956 6.04E-05 0.994
IlePhe 1.62E-05 0.991 2.54E-05 0.984 2.58E-06 0.912 9.81E-05 0.972
IleHis 5.06E-06 0.935 7.06E-06 0.962 9.58E-07 0.928 5.89E-05 0.942
IleAla 5.38E-05 0.990 4.43E-05 0.998 5.55E-07 0.939 4.97E-05 0.991
IleVal 2.12E-06 0.861 5.02E-06 0.958 5.57E-07 0.897 4.52E-05 0.989
IleLys 1.31E-06 0.159 -9E-06 -0.775 1.61E-06 0.841 4.98E-05 0.924
IleCit 3.09E-05 0.993 3.94E-05 0.993 6.65E-07 0.842 6.68E-05 0.997
IleTrp 1.28E-05 0.993 3.58E-05 0.998 1.38E-06 0.901 0.000458 1.000
AsnAsn 2.78E-07 0.371 0.000325 1.000 9.34E-05 0.997 8.45E-05 1.000
AsnAib -4.6E-07 -0.524 1.43E-06 0.559 6.3E-07 0.936 7.56E-05 0.997
AsnPhe 1.96E-06 0.941 0.000272 0.999 4.62E-05 0.993 5.8E-05 0.994
AsnHis 3.27E-06 0.977 0.00011 1.000 1.92E-05 0.998 5.53E-05 0.991
AsnAla 1.27E-05 0.981 0.000284 0.999 6.32E-05 0.996 5.66E-05 0.993
AsnVal 2.22E-06 0.948 0.000124 0.999 4.8E-05 0.996 2.01E-05 0.869
AsnLys 8.83E-06 0.957 0.000137 0.998 2.71E-05 0.997 6.19E-05 0.976
AsnCit 8.18E-06 0.966 0.000152 1.000 3.8E-05 0.997 2.98E-05 0.970
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